Industry
Samsung Biologics readies for potential Alzheimer’s deals
Jan. 16, 2020
SAN FRANCISCO -- Kim Tae-han, the CEO of Samsung Biologics, said Wednesday that he expects to take on contract manufacturing deals for Alzheimer’s disease treatments, and that the company will be ready when the opportunity arises. Kim, speaking to investors at JP Morgan Healthcare Conference 2020 in San Francisco, said Biogen’s Alzheimer’s pipeline aducanumab has proven its efficacy through data. The only hurdle to US Food and Drug Administration approval, Kim said, was the com